Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study

Menéndez, Edelmiro; Delgado, Elías; Fernández‐Vega, Francisco; Prieto, Miguel J.; Bordiú, Elena; Calle, Alfonso; Carmena, Rafael; Castaño, Luís; Catalá, Miguel; Franch, Josep; Gaztambide, Sonia; Girbés, Juan; Goday, Albert; Gomis, Ramón; López-Alba, Alfonso; Martı́nez-Larrad, Marı́a Teresa; Mora-Peces, Inmaculada; Ortega, Emilio; Rojo-Martínez, Gemma; Serrano-Rı́os, Manuel; Urrutia, Inés; Valdés, Sergio; Vázquez, José Antonio; Vendrell, Joan; Soriguer, Federico

doi:10.1016/j.rec.2015.11.034

Cited by 56 publications

(66 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…that set in at 8%, about four points below the Spanish average. On the other hand, our investigation shows a prevalence of hypertension at 18.2%, which is lower than other investigations carried out in our country (25.5%-42.6%)24,25 ; however, regarding this difference, it should be noted that we only collected previously diagnosed and treated hypertension. The studies above had a prevalence of 12.9% and 26.7%, respectively.…”

contrasting

confidence: 93%

Rationale, design and preliminary results of the GALIPEMIAS study (prevalence and lipid control of familial dyslipidemia in Galicia, northwest Spain)

et al. 2018

View full text Add to dashboard Cite

Aims There is little information on the familial nature of dyslipidemias in the Spanish population. This knowledge could have potential diagnostic and treatment implications. The objective of the GALIPEMIAS study was to determine the prevalence of familial dyslipidemia in Galicia, as well as determine the degree of lipid control in the participants. Prevalence of atherosclerotic cardiovascular disease (ASCVD) was also estimated. This paper presents the design, methodology and selected preliminary results. Methodology A cross‐sectional study was performed in the population aged ≥18 years using cluster sampling and then random sampling. A sample of 1000 subjects was calculated and divided into three sequential phases with a specific methodology for each one. Phase I: selection of subjects from the general population and collection of informed consent documents; Phase II: collection of data from the digital clinical history to select subjects with dyslipidemia according to study criteria; Phase III: personal interview, blood analysis, family tree, and definitive diagnosis of dyslipidemia. Prevalence of different diseases and active medication was analysed. Corrected prevalence (to the reference population) of different risk factors and ASCVD was estimated. Results Phase I participation was 89.5%. We extracted complete information from 93% of the participants (Phase II). According to the study′s own criteria, 56.5% (n = 527) of the participants had some form of dyslipidemia and almost 33.7% of them had familial dyslipidemia with autosomal dominant inherit pattern. The corrected prevalence of ASCVD was 5.1% (95% CI 3.1‐7.2). Conclusions Dyslipidemia was the most prevalent cardiovascular risk factor in our population with an autosomal dominant inheritance pattern in one out of every three dyslipidemia cases. Approximately, 5.1% of the sample population aged ≥18 has suffered an episode of ACVD.

show abstract

contrasting

confidence: 93%

Rationale, design and preliminary results of the GALIPEMIAS study (prevalence and lipid control of familial dyslipidemia in Galicia, northwest Spain)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…2%, 31.4% and 7.9% respectively) and SpA patients(19.3%, 34.7% and 6.0% respectively). Regarding countries from Mediterranean region, we noted that the estimated prevalence of hypertension, dyslipidemia and T2DM was 42.6 %, 49.5 % and 13.6 % in healthy individual (reference data from Spain)[39,40] and 19.4 %, 14.4 % A c c e p t e d M a n u s c r i p t and 6.4 % in our SpA patients. In relation to obesity, we observed that the global prevalence was estimated at 29.7 % in healthy individuals and 20.7 % in SpA patients.Thus, our data suggest that disease phenotype may be involved in the development of CV comorbidities in SpA patients.…”

mentioning

confidence: 72%

Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Hypertension is defined as high blood pressure (HBP) levels compared to normal blood pressure values: systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg (Menéndez et al., ). In mammals, blood pressure is regulated primarily by the renin–angiotensin system (RAS).…”

Section: Introductionmentioning

confidence: 99%

Chia Seed (Salvia hispanica L.) Pepsin Hydrolysates Inhibit Angiotensin‐Converting Enzyme by Interacting with its Catalytic Site

Pablo-Osorio

Mojica

Urías‐Silvas

2019

Journal of Food Science

View full text Add to dashboard Cite

High blood pressure can lead to cardiovascular diseases. The objective of this work was to obtain protein hydrolysates with antihypertensive potential from chia oil industry meal byproduct. Chia seed protein isolates (CPIs) were obtained from chia seed meal byproduct. CPI was hydrolyzed using different proteases (alcalase, pepsin, trypsin, and αchymotrypsin) and their biological potential was evaluated using in vitro and in silico approaches. Chia seed pepsin protein hydrolysate showed the highest angiotensin-converting enzyme inhibition potential IC 50 of 0.128 mg/mL (P < 0.05) compared to the rest of hydrolysates. Peptide sequence LIVSPLAGRL presented the lowest predicted binding energy and highest inhibition potential (-9.5 kcal/mol) compared to other sequenced peptides and positive controls (captopril and lisinopril). Chia peptides showed potential to block angiotensin-converting enzyme by interacting with its catalytic site. Chia seed oil industry meal byproduct could be used as an inexpensive source of protein and bioactive peptides with antihypertensive potential.Practical Application: This research shows an upcycling alternative for chia oil industry byproduct. Chia meal is a rich source of protein and can be used to generate bioactive peptides with antihypertensive potential. Chia protein isolate was obtained from chia meal and hydrolyzed using different enzymes, pepsin showed the highest antihypertensive potential. Chia meal waste could be a low-cost source of protein and protein hydrolysates that could be used as a food ingredient with antihypertensive potential.

show abstract

Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study

Cited by 56 publications

References 22 publications

Rationale, design and preliminary results of the GALIPEMIAS study (prevalence and lipid control of familial dyslipidemia in Galicia, northwest Spain)

Rationale, design and preliminary results of the GALIPEMIAS study (prevalence and lipid control of familial dyslipidemia in Galicia, northwest Spain)

Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project

Chia Seed (Salvia hispanica L.) Pepsin Hydrolysates Inhibit Angiotensin‐Converting Enzyme by Interacting with its Catalytic Site

Contact Info

Product

Resources

About